Evgen Pharma Share Discussion Threads

[moneymunch] 06/10/2020 08:03

Lol bumpa, exactly right....some punters are clueless or are just tying to find some negative....it's his employment package FFS...;-)

[bumpa33] 06/10/2020 07:55

It’s an options package, they all get them, the question is whether he’s going to earn them or not.

[lovewinshatelosses] 06/10/2020 07:41

He still could have made a statement of intent, outside of the generous terms of his package. If he does do so soon, then I will buy more as well. As I have done with other companies, where the directors show they are not just in it for the pay cheque. Not a positive first impression to my mind, but ultimately the share price will do the talking in the weeks and months ahead.

[moneymunch] 06/10/2020 07:29

Give the bloke a chance, it's part of his employment package and obviously an incentive to grow the company....Good news next...Gl ;-)

[nobbygnome] 06/10/2020 07:28

As peanut says, disappointing to see him sorting out his own wealth straight away. A sizeable purchase of stock is required very soon to give confidence to the market.

[lovewinshatelosses] 06/10/2020 07:22

What is the specific criteria for that bunch of free shares?
He had better get the share price to at least double where we currently are, and in short order.
I know a lot of companies dole out share freebies like candy, but an opportunity has been missed to demonstrate alignment with shareholders via buying a decent chunk from his own pocket.
Let's see what the market thinks anyway.

[moneymunch] 06/10/2020 07:17

No problem...;-)

[peanut100] 06/10/2020 07:12

The option price better be north of 50p

[moneymunch] 06/10/2020 07:10

Lol...all part of the process and terms of his employment.....Good news next. Gl ;-)

[peanut100] 06/10/2020 07:08

Or at least buy some shares in the market

[peanut100] 06/10/2020 07:07

Nice to see first thing he does is sort out his back pocket. How about some proper news/update

[moneymunch] 06/10/2020 07:05

Incentives in place for the new CEO to get the ball rolling. Gla ;-)

[stockhunters] 05/10/2020 08:42

all covid stocks going nutty today evg next update soon

[moneymunch] 05/10/2020 08:24

Cheers richbw, undoubted UPside potential and so let's hope the new CEO has plenty of positive news to report in the coming days and weeks. Gl ;-)

[richbw] 05/10/2020 07:33

Thankyou Moneymunch, very interesting!

[moneymunch] 04/10/2020 17:56

ps and not forgetting the very recent WOW discovery of STAT3 being the "Key to immune system inflammation discovered"....and so plenty of mileage one would have thought. Gl ;-)

[moneymunch] 04/10/2020 17:52

Yep, and since SFX-01 was selected for Covid-19 patient trials because of its Nrf2 activation, it now looks like that its STAT3 activator properties could also be of benefit against Covid-19....and so maybe a dual mechanism for SFX-01 as an Nrf2 activator and also STAT3 activator as a potent therapy against ARDS ....Gl ;-)

19/9/20

J Cell Mol Med. 2020 Sep 19. doi:

10.1111/jcmm.15838. Online ahead of print.

ABSTRACT

The SARS-coronavirus 2 is the aetiologic agent COVID-19. ACE2 has been identified as a cell entry receptor for the virus. Therefore, trying to understand how the gene is controlled has become a major goal. We silenced the expression of STAT3α and STAT3β, and found that while silencing STAT3α causes an increase in ACE2 expression, silencing STAT3β causes the opposite effect. Studying the role of STAT3 in ACE2 expression will shed light on the molecular events that contribute to the progression of the disease and that the different roles of STAT3α and STAT3β in that context must be taken in consideration. Our results place STAT3 in line with additional potential therapeutic targets for treating COVID-19 patients.

[bocker01] 04/10/2020 17:30

So a genuinely very serious trial and about a lot more than merely Covid 19. Area with vast vast commercial potential. On the money, Money

[bocker01] 04/10/2020 17:30

So a genuinely very serious trial and about a lot more than merely Covid 19. Area with vast commercial potential. On the money, Money!

[moneymunch] 04/10/2020 17:15

News of first patients administered imminent...imho...Gl ;-)

Research title

A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in COVID-19 progression

Summary

University of Dundee and Evgen Pharma PLC, with funding from LifeArc, are set to commence clinical trial testing of an investigational medicinal product in 300 hospitalised COVID-19 patients. Researchers have identified that one of Evgen’s existing products, SFX-01, could reduce the impact of COVID-19 disease by preventing Acute Respiratory Distress Syndrome (ARDS), a common and often deadly symptom of severe cases of COVID-19.

A major challenge in the treatment of COVID-19 is the development of slowly worsening lung damage, known as Acute Respiratory Distress Syndrome (ARDS). This requires intensive care treatment with ventilation until the inflammation is resolved and the lungs can heal.

Nrf2 is a transcription factor (a naturally-occurring protein) which forms part of the body’s defences against inflammatory and oxidative stress, such as the inflammation that occurs during a severe viral infection. It is hypothesised that increasing the levels of active Nrf2 in patients with COVID-19 could improve recovery and prevent the need for ventilation.

SFX-01, a stable form of the natural compound sulforaphane, is an orally administered investigational medicinal product that activates Nrf2 and has been tested in over 130 patients to date in clinical trials (in healthy volunteers and patients suffering from breast cancer or a rare type of brain haemorrhage).

Researchers secured funding from LifeArc to conduct an investigator led, prospective, randomised, double-blind placebo-controlled trial, conducted in the UK, of patients hospitalised with COVID-19.

Investigating a sample size of 300 subjects, the study will compare outcomes for 300mg SFX-01 taken orally, once daily, plus best standard of care (BSC) versus placebo taken orally, once daily plus BSC. The primary outcome of the trial is the clinical status of patients on day 15 based on a seven point scale, recommended by the World Health Organisation as the optimal clinical trial endpoint for COVID-19 studies.

[moneymunch] 04/10/2020 17:10

Lol...whatever!!!...;-)

ps SFX-01 has been selected fot Covid-19 patient trials because industry and academia believe it could be a potent therapy for ARDS...Covid-19 is secondary in its potential but obviuosly the majority of severe Covid-19 patients die from ARDS related problems....and so potentially SFX-01 for ARDS related diseases will be around long after Covid-19 is defeated....although personally i think Covid-19 will be around for many years , regardless of any vaccine....Gla ;-)



General Information about ARDS


Acute respiratory distress syndrome (ARDS) is defined as an acute process, which results in moderate to severe loss of lung function.

Approximately 150,000-200,000 Americans will be diagnosed with ARDS each year. Worldwide, that number is approximately 2.2 million.

There is no known prevention for ARDS at the present time. Nor is there any known cure. ARDS patients are treated with supportive care, most often in the Intensive Care Unit.

Although ARDS is always a critical syndrome, more than half of the patients who are diagnosed with ARDS survive.

[nobbygnome] 04/10/2020 16:47

Sigh. Where in that statement does it say the potential benefit will be none. It won't be approved because they won't even bother to submit it because it will be too late. I do think the benefit will be marginal at best however, and that will be part of the overall assessment.

[moneymunch] 04/10/2020 16:21

Ps...from the lead investigator of SFX-01's extensive and comprehensive phase 2/3 patient trials...Gla holders...:-)



James D Chalmers
@ProfJDChalmers

A link to the presentation of the interferon beta data from todays conference call. Encouraging data but we should be cautious in interpreting small trials, particularly when full data not available yet #COVID19

[moneymunch] 04/10/2020 16:17

Lol..that's right, never let the truth get in the way...eh....this is what you posted on SFX-01's Covid-19 potential, nothing to do how long it might take...now run along little man...this is the EVG thread...Gl ;-)



Nobbygnome - 19 Sep 2020 - 10:00:10

EVG>> MM

I haven't laughed so much for ages. SFX-01 a competitor for SNG001? That is such a completely ridiculous statement. I will put my head above the parapet and say that IMHO SFX-01 will never be approved for use in Covid 19 patients.

Meanwhile SNG001 easily has the best data in Covid 19 patients from a placebo controlled trial..

[nobbygnome] 04/10/2020 16:00

And you are misquoting me which is not unusual as facts and you only have a loose association. I actually said it was a 'waste of time' trialing SFX01 in Covid 19. The main reason for that is it will be far too late once the results are obtained assuming they are positive.

After all you thought the low rate of deaths in Scotland back in the Summer was due to the SFX01 trial. Talk about the truth not getting in the way of a good story!